Please login to the form below

Not currently logged in
Email:
Password:

Xultophy

This page shows the latest Xultophy news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... Xultophy’s performance helped prop up the insulin category as it copes with a slide in sales of top seller Levemir (insulin

Latest news

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

  • Sanofi wins EU approval for new diabetes combination Suliqua Sanofi wins EU approval for new diabetes combination Suliqua

    same day as rival therapy Xultophy, Novo Nordisk's insulin degludec and liraglutide combination. ... In the EU, however, Xultophy has the edge as it received regulatory approval in 2014 in Europe, where it is marketed as IDegLira.

  • Sanofi launches insulin combo Soliqua in US Sanofi launches insulin combo Soliqua in US

    Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... 2016. Xultophy is already available in Europe under the IDegLira trade name, but Novo Nordisk has not yet

  • FDA clears rival diabetes combos from Sanofi and Novo Nordisk FDA clears rival diabetes combos from Sanofi and Novo Nordisk

    FDA clears rival diabetes combos from Sanofi and Novo Nordisk. Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out. ... In the case of Xultophy, the combination is based on Novo's basal insulin Tresiba (insulin

  • Sanofi trumpets new IGlarLixi data after regulatory delay Sanofi trumpets new IGlarLixi data after regulatory delay

    Novo Nordisk's IDeglira/Xultophy (insulin degludec/liraglutide) is already on the market in Europe, but Sanofi had been hoping to get IGlarLixi to market in the US first with the ... Novo Nordisk is due to hear a verdict on Xultophy later this month.

More from news
Approximately 13 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics